Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Volcano lauds revised guidelines for treating severe coronary artery disease patients

Volcano Corporation, a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, reacted positively to the new guidelines for treating coronary disease and heart attacks using percutaneous coronary intervention (PCI), a procedure that treats narrowed blood vessels.

23 Dec 2009

Study reveals patient characteristics can affect image quality of MDCT scans

A large multicenter international trial found that the image quality of multi-detector computed tomography (MDCT) scans, used for the noninvasive detection of coronary artery disease, can be significantly affected by patient characteristics such as ethnicity, body mass index (BMI), and heart rate, according to a study in the January issue of the American Journal of Roentgenology.

23 Dec 2009

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

Resverlogix Corp. ("Resverlogix" or the "Company") announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with stable coronary artery disease (CAD).

23 Dec 2009

MRG: Chinese drug-eluting stent market to reach more than $900 million by 2014

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, health care reforms in China supported rapid expansion of the Chinese drug-eluting stent market in 2009, and will continue to fuel growth in the coming years.

17 Dec 2009

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

St. Jude Medical, Inc. applauds the updated level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI).

17 Dec 2009

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

AstraZeneca and the University of Virginia (UVa) in Charlottesville, today announced that they have entered into a strategic research collaboration to enhance development of new treatments primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

15 Dec 2009

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Women with suspected coronary artery disease (CAD) who report taking antidepressant and anti-anxiety medications have an increased risk of cardiovascular events, including heart attacks and strokes, and death compared to women not taking these medications, according to researchers at the Uniformed Services University of the Health Sciences (USU).

15 Dec 2009

Cardiologists receive K23 research grant from NIH

Brian H. Annex, M.D., chief of the Division of Cardiovascular Medicine at the University of Virginia Health System, says he feels like the coach of a championship team. "Going three for three is truly extraordinary," he says with a mixture of pride and awe in his voice.

10 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

TRYTON-LM clinical study enrolls first two patients

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the enrollment of the first two patients in TRYTON-LM, a prospective, single-arm study evaluating the feasibility of the Tryton stent in conjunction with Abbott’s XIENCE PRIME Everolimus Eluting Coronary Stent System to treat stable patients with complex de novo bifurcation lesions involving the left main coronary artery.

9 Dec 2009

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Results from a new study showed patients with type 2 diabetes who also had coronary artery disease (CAD) experienced greater antiplatelet activity with the investigational antiplatelet drug prasugrel compared to Plavix(R) (clopidogrel). Patients who received a 60 mg loading dose and 10 mg maintenance dose of prasugrel achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix.

4 Dec 2009

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is important for the recruitment of white blood cells into the atherosclerotic plaque.

4 Dec 2009

Breastfeeding a child may lower a woman's risk of developing Metabolic Syndrome

Breastfeeding a child may lower a woman's risk of developing Metabolic Syndrome, a condition linked to heart disease and diabetes in women, according to a Kaiser Permanente study that was published today online ahead of print and will appear in the February issue of Diabetes, a journal of the American Diabetes Association.

4 Dec 2009

Breastfeeding reduces a woman's risk of developing Metabolic Syndrome

3 Dec 2009

Exercise remains one of the most effective interventions for peripheral artery disease

Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.

3 Dec 2009

Research finds change in the outlook of people with type 2 diabetes and heart disease

The outlook for individuals with type 2 diabetes and coronary artery disease is not as grim as originally believed, according to new Saint Louis University research published in Circulation, the Journal of the American Heart Association.

2 Dec 2009

Overall use of blood-thinning agents not improving despite more options

Since 1999, stroke survivors have been advised to use aspirin, prescription antiplatelet agents, or prescription anticoagulants to help avoid another stroke. Many large surveys of the U.S. population have reported the use of aspirin for secondary prevention, but commonly combine people with stroke and coronary artery disease, and only rarely report the use of antithrombotic agents other than aspirin.

2 Dec 2009

European Commission and the EMEA approve Angiox in primary PCI for STEMI

The Medicines Company announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

1 Dec 2009

Clinical trail shows PAD patients also experience asymptomatic heart disease

Results of a randomized, controlled clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) reveal that one in five patients with narrowing or blockage in arteries that supply blood to the legs and other parts of the body also have significant but silent coronary artery disease.

1 Dec 2009

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Volcano lauds revised guidelines for treating severe coronary artery disease patients

Study reveals patient characteristics can affect image quality of MDCT scans

US Phase 2 clinical trial of RVX-208 commenced by Resverlogix

MRG: Chinese drug-eluting stent market to reach more than $900 million by 2014

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

AstraZeneca, UVa announce collaboration in development of new treatments for CAD and PAD

Antidepressant and anti-anxiety medications linked to increased risk of cardiovascular events and death

Cardiologists receive K23 research grant from NIH

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

TRYTON-LM clinical study enrolls first two patients

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

Breastfeeding a child may lower a woman's risk of developing Metabolic Syndrome

Breastfeeding reduces a woman's risk of developing Metabolic Syndrome

Exercise remains one of the most effective interventions for peripheral artery disease

Research finds change in the outlook of people with type 2 diabetes and heart disease

Overall use of blood-thinning agents not improving despite more options

European Commission and the EMEA approve Angiox in primary PCI for STEMI

Clinical trail shows PAD patients also experience asymptomatic heart disease

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in